SEC Form 4 · accession 0001193125-26-296249
Cogent Biosciences, Inc. · COGT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Jean Ferrante
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001622229
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $38.48 | Jul 1, 2026 | A | 627 | A | Jul 1, 2026 | Jul 1, 2036 | Common Stock | 627 | 627 | D |
Explanation of responses
- F1The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.